Izumi Yamatani, Akio Aono, Keiji Fujiwara, Takahiro Asami, Keisuke Kamada, Yuta Morishige, Yuriko Igarashi, Kinuyo Chikamatsu, Yoshiro Murase, Hiroyuki Yamada, et al. In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates. Microbiology spectrum. 2024. e0008424
Yutaro Akiyama, Noriko Iwamoto, Keisuke Kamada, Atsushi Yoshida, Asami Osugi, Satoshi Mitarai, Tetsuya Suzuki, Kei Yamamoto, Maki Nagashima, Tetsuya Horai, et al. Aortic endograft infection by Mycobacterium abscessus subsp. massiliense with acquired clarithromycin resistance: a case report. BMC infectious diseases. 2023. 23. 1. 694-694
Sho Nakakubo, Naoki Kishida, Kenichi Okuda, Keisuke Kamada, Masami Iwama, Masaru Suzuki, Isao Yokota, Yoichi M Ito, Yasuyuki Nasuhara, Richard C Boucher, et al. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study. The Lancet. Infectious diseases. 2023
Keiji Fujiwara, Akio Aono, Takahiro Asami, Kozo Morimoto, Keisuke Kamada, Yuta Morishige, Yuriko Igarashi, Kinuyo Chikamatsu, Yoshiro Murase, Hiroyuki Yamada, et al. In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus. Antimicrobial agents and chemotherapy. 2023. 67. 6. e0157922
Sho Nakakubo, Naoki Kishida, Kenichi Okuda, Keisuke Kamada, Masami Iwama, Masaru Suzuki, Isao Yokota, Yoichi M Ito, Yasuyuki Nasuhara, Richard C Boucher, et al. Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan. medRxiv : the preprint server for health sciences. 2023
